Biotech Stock Intel
Catalyst CalendarPDUFA CalendarMover SignalsCompany Screener
Disclaimer: Biotech Stock Intel is an independent research platform. Information is provided for informational purposes only and is not investment or medical advice. Always verify catalyst dates against primary sources and conduct your own research.
Biotech Stock Intel© 2026 Biotech Stock Intel
AboutMethodologyTermsPrivacy
Biotech Stock Intel
Catalyst CalendarPDUFA CalendarMover SignalsCompany Screener
Home/Stocks/ALMS/Catalyst
Phase 2bData readout

ESK-001

Systemic lupus erythematosus

ALMSAlumis
Expected catalystSeptember 30, 2026Company guidance: Sep 30, 2026

Catalyst overview

Event details

Drug or asset
ESK-001
Development stage
Phase 2b
Event type
Data readout
Indication
Systemic lupus erythematosus
Research signalsHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 2b data readout for ESK-001 in Systemic lupus erythematosus . The expected timing is based on the latest available company guidance and may change.

Development notes

05/14/26:- LUMUS Ph2b SLE topline data remains expected in Q3 2026. 08/13/26:- LUMUS Ph2b SLE topline data remains expected in Q3 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

More from ALMS

Related pipeline programs

Phase 2

ESK-001

Moderate-to-severe plaque psoriasis

View company pipeline

Company

Alumis

ALMS · NasdaqGS
Industry
Biotechnology
Pipeline assets
5
View ALMS research

BioPharma Pro

Track every date change

Watchlists, source history and catalyst alerts will be available with Pro.

Start free

Updated Aug 23, 2026. Dates can change; this is not investment advice.

Disclaimer: Biotech Stock Intel is an independent research platform. Information is provided for informational purposes only and is not investment or medical advice. Always verify catalyst dates against primary sources and conduct your own research.
Biotech Stock Intel© 2026 Biotech Stock Intel
AboutMethodologyTermsPrivacy